3-Bromopyruvic acid

  Cat. No.:  DC22490   Featured
Chemical Structure
1113-59-3
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
A glycolytic inhibitor that inhibits hexokinase II activity, suppresses ATP production, and induces endoplasmic reticulum (ER) stress.
Cas No.: 1113-59-3
Chemical Name: 3-Bromopyruvic acid
Synonyms: 3-Bromopyruvic acid;3-BROMO-2-OXOPROPANOIC ACID;3-BROMO-2-OXOPROPIONIC ACID;BROMOPYRUVIC ACID;3-bromo-2-oxo-propanoicaci;3-bromopyruvate;beta-bromopyruvicacid;bromopyruvate;bromo-pyruvicaci;3-BROMOPYRUVIC ACID CRYSTALLINE;Bromopyruvicacidhydrate;3-BROMO-2-OXOPROPANOICACID(3-BROMOPYRUVICACID);2-Oxo-3-bromopropanoic acid;2-Oxo-3-bromopropionic acid;3-BROMO-2-OXO-PROPIONIC ACID;3-BromopYHuvic acid;3-BROMOPYRUVIC ACID HYDRATE;3-BROMOPYRUVICACID(3-BROMOPYRUVATE);Hexokinase II Inhibitor II, 3-BP;PROPANOIC ACID,3-BROMO-2-OXO-;3-Bromo-2-oxopropionic Acid;NS00023565;NS00023565;EN300-67360;EN300-67360;CHEBI:95046;CHEBI:95046;Bromopyruvic acid; 3-bromo-2-oxopropanoic acid;Bromopyruvic acid; 3-bromo-2-oxopropanoic acid;Bromopyruvic acid, >=97.0% (T);Bromopyruvic acid, >=97.0% (T);3-bromo-2-oxopropanoic acid;3-Bromopyruvic acid;3-bromo-2-oxopropanoic acid;3-Bromopyruvic acid;bromopyruvic acid;bromopyruvic acid;3-BP;3-BP;.beta.-Bromopyruvic acid;NSC-62343;.beta.-Bromopyruvic acid;NSC-62343;EINECS 214-206-5;NSC 11731;EINECS 214-206-5;NSC782120;NSC 11731;FT-0623262;NSC782120;BRD-K92980438-001-01-7;FT-0623262;BRD-K92980438-001-01-7;Z1079181768;Z1079181768;Bromopyruvicacid;Bromopyruvicacid;Hexokinase II Inhibitor II, 3-BP - CAS 1113-59-3;Hexokinase II Inhibitor II, 3-BP - CAS 1113-59-3;3-Bromo-2-oxopropionic acid;3-Bromo-2-oxopropionic acid;NSC-11731;NSC-11731;Propanoic acid, 3-bromo-2-oxo-;3-bromo-2-oxo-propionic acid;Propanoic acid, 3-bromo-2-oxo-;J-650255;3-bromo-2-oxo-propionic acid;J-650255;1113-59-3;1113-59-3;BPV;BPV;CS-5517;NSC11731;CS-5517;Q3608257;NSC11731;NSC62343;Q3608257;3-BrPA;NSC62343;MFCD00002587;3-BrPA;Pyruvic acid, bromo-;HY-19992;MFCD00002587;3-Bromopyruvic acid hydrate,98;Pyruvic acid, bromo-;HY-19992;B1153;SCHEMBL8126;3-Bromopyruvic acid hydrate,98;bromo-2-oxopropanoic acid;B1153;beta-Bromopyruvic acid;SCHEMBL8126;s5426;bromo-2-oxopropanoic acid;AM84337;beta-Bromopyruvic acid;AS-16146;s5426;AKOS015892643;AM84337;63JMV04GRK;AS-16146;NSC 62343;AKOS015892643;63JMV04GRK;3-bromopyruvic acid;HMS3866H13;NSC 62343;CCG-266336;3-bromopyruvic acid;Hexokinase II Inhibitor II;3-BP;HMS3866H13;J-511892;CCG-266336;UNII-63JMV04GRK;Hexokinase II Inhibitor II;3-BP;BRN 1746786;J-511892;3-Bromo-2-oxopropanoic acid #;UNII-63JMV04GRK;CHEBI:131461;BRN 1746786;3-bromo-2-oxopropanoic acid;3-Bromo-2-oxopropanoic acid #;3-bromo-2-keto-propionic acid;CHEBI:131461;NSC-782120;3-bromo-2-oxopropanoic acid;HMS3741K19;3-bromo-2-keto-propionic acid;3-bromopyruvicacid;NSC-782120;DTXSID7040940;HMS3741K19;CHEMBL177837;3-bromopyruvicacid;NCIOpen2_000241;DTXSID7040940;CHEMBL177837;NCIOpen2_000241
SMILES: O=C(O)C(CBr)=O
Formula: C3H3BrO3
M.Wt: 166.96
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: A glycolytic inhibitor that inhibits hexokinase II activity, suppresses ATP production, and induces endoplasmic reticulum (ER) stress; potentiates acetate-induced apoptosis and anti-proliferative effect in CRC cells; abrogates MUC1-mediated radiation resistance both in vitro and in vivo pancreatic cancer models, by reducing glucose flux into nucleotide biosynthetic pathways and enhancing DNA damage.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC31074 Isopropyl myristate Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75202 Fosaprepitant free acid Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74557 PREX-in1 PREX-in1 is a specific small-molecule inhibitor of P-Rex1 and P-Rex2 Rac-GEF activity with IC50 of 4.5 uM (P-Rex1 DHPH Rac-GEF activity) in liposome-based GEF assay, inhibits P-Rex1 and P-Rex2 through their catalytic DH domain.
DC74555 GYS32661 GYS32661 (GYS 32661) is a potent Rac inhibitor capable of inhibiting both Rac1 and Rac1b, inhibited activated Rac1 with IC50 of 1.18 uM in in vitro pull-down assays.
DC74540 MTX-3937 MTX-3937 is a small-molecule inhibitor targeting Siglec-9 (Sialic acid-binding immunoglobulin-type lectin-9), a member of the Siglec family of immunomodulatory receptors. Siglec-9 is primarily expressed on immune cells, such as myeloid cells and natural killer (NK) cells, and plays a role in regulating immune responses by transmitting inhibitory signals through its intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs).
DC74539 L557-0155 L557-0155 is a small molecule inhibitor of VSIG-8, prevents VSIG-8 binding to VISTA, promotes cytokine production and cell proliferation in PBMCs and suppresses melanoma growth.
DC74528 K284 K284 is a selective small molecule inhibitor of chitinase 3 like1 (CHI3L1) with strong binding affinity (Kd=-9.7 kcal·mol-1), inhibits lung metastasis by blocking IL-13Rα2-mediated JNK-AP-1 signals.
DC74225 YB-537 YB-537 (YB537) is a potent, highly specific quinone reductase 2 (QR2) inhibitor with IC50 of 3 nM, shows no activity against QR1 (IC50>10 uM).
DC74224 XST-20 XST-20 is a small molecule that selectively targets the DNA-binding domain (DBD) of FOXM1, atranscription factor involved in cell cycle progression, proliferation, and cancer development. Witha surface plasmon resonance (SPR)-derived binding affinity (Kd) of 20 uM, XST-20 effectivelysuppresses FOXM1's transcriptional activities, making it a promising candidate for targetingFOXM1-driven cancers, such as ovarian cancer.
DC74223 X-Neu5Ac X-Neu5Ac (sodium) is a substrate for chromogenic assay of neuraminidase activity in bacterial expression systems; with a Km of 0.89 mM for neuraminidase.
X